16th Nov 2007 09:36
Meldex International PLC16 November 2007 For Immediate Release 16 November 2007 Meldex International Plc TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Meldex International Plc 2. Reason for the notification (please tick the appropriate box or boxes): A acquisition or disposal of voting rights 3. Full name of person(s) subject to the notification obligation: Barclays PLC 4. Full name of shareholder(s) (if different from 3.) n/a 5. Date of the transaction and date on which the threshold is crossed or reached: November 14, 2007 6. Date on which issuer notified: November 15, 2007 7. Threshold(s) that is/are crossed or reached: 5% to 6% 8. Notified details: A: Voting rights attached to shares Class/type Situation previous to the Resulting situation after the triggeringof shares Triggering transaction transactionif possibleusing the Number of Number of Number of Number of voting % of votingISIN CODE Shares Voting Rights shares rights rights Direct Direct Indirect Direct IndirectGB0032681628 11,538,725 11,538,725 11,590,281 0 11,590,281 0.00 6.01 B: Financial Instruments Resulting situation after the triggering transactionType of Expiration Exercise/ Number of voting rights that may be % offinancial date Conversion acquired if the instrument is votinginstrument exercised/ converted. rights Period/ Daten/a n/a n/a n/a n/a Total (A+B) Number of voting rights % of voting rights 11,590,281 6.01% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable n/a Proxy Voting: 10. Name of the proxy holder: n/a 11. Number of voting rights proxy holder will cease to hold: n/a 12. Date on which proxy holder will cease to hold voting rights: n/a For further information: Meldex International Plc + 44 (0) 20 7098 9881Richard Trevillion, CEOSteve Martin, CDOHiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000Rebecca Skye DietrichMark Court About Meldex International Plc Meldex International plc is an innovative specialty pharmaceutical and OTCproduct Company. Listed on London's AIM in May 2003, the Company has over 80patents granted or in application within 24 patent families and has productdevelopment agreements and strategic alliances with several global healthcarecompanies. Meldex has acquired sales and marketing resources within Europe andthe US as a launch mechanism for its own pharmaceutical products. Meldexacquired the Melbrosin business in June 2007 for a consideration of up to €35m,Melbrosin's focus is on consumer over the counter health care products based onsubstances of natural and plant origin, which are developed into consumerorientated brands then scaled, produced and distributed by Melbrosin. TheMelbrosin complements the prescription pharmaceutical sales and marketingbusiness created and expanded in 2006. The business continues to develop innovative delivery mechanisms enhancing bothits own product range and those of selected partners using its proprietaryXGELTM polymer technology. For further information please go towww.meldexinternational.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Barclays